Ignite Creation Date:
2025-12-24 @ 11:30 PM
Ignite Modification Date:
2026-02-21 @ 10:01 PM
Study NCT ID:
NCT04223856
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-06-13
First Post:
2020-01-06
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
Sponsor:
Astellas Pharma Global Development, Inc.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
SGN22E-003
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None